Company Filing History:
Years Active: 1993
Title: Innovations in Inhaler Technology: The Contributions of Richard N. Dalby
Introduction
Richard N. Dalby, an esteemed inventor based in Richmond, VA, has made significant advancements in the field of aerosol delivery systems. With a total of three patents to his name, Dalby’s work focuses on improving the formulation and delivery methods of medications through metered dose inhalers (MDIs). His innovative approaches have the potential to enhance treatment efficacy while mitigating environmental concerns associated with traditional propellants.
Latest Patents
Dalby’s latest patents delve into the formulation and delivery of beclomethasone dipropionate (BDP). His first notable patent outlines a method where BDP forms a clathrate with less harmful propellants such as HCFC-123, dimethyl ether (DME), and HCFC-141b. These propellants are a safer alternative to chlorofluorocarbon (CFC) propellants, traditionally used in MDIs, and contribute to less atmospheric harm. This formulation enables remicronization and suspension for effective use in MDIs, ensuring that BDP is efficiently delivered when using blends that completely dissolve it.
Another significant patent centers around aerosol formulations for MDIs. This innovation includes using 1,1,1,2-tetrafluoroethane as well as combinations with various hydrocarbon blends. The extensive examination of factors such as density, vapor pressure, and compatibility of elastomer seals has led to the creation of formulations that present as viable alternatives to ozone-depleting aerosols.
Career Highlights
Richard N. Dalby’s career is marked by a dedication to improving inhalation therapy through meticulous research and inventive formulations. Affiliated with Virginia Commonwealth University, he has leveraged his academic background to push the boundaries of pharmaceutical delivery systems. His commitment to developing environmentally friendly solutions reflects a broader trend in medical science towards sustainable practices.
Collaborations
Dalby’s innovative work has been further enriched through his collaboration with his coworker, Peter R. Byron. Together, they have driven advancements in aerosol technology, addressing critical issues related to medication delivery and environmental safety.
Conclusion
In conclusion, Richard N. Dalby stands out as a significant inventor in the realm of inhalation therapies, important for both his scientific contributions and his commitment to environmentally sound practices. His latest patents provide a glimpse into the future of pharmaceutical delivery, paving the way for safer, more effective treatment options for patients reliant on metered dose inhalers.